Annu Rev Med. 2025 Oct 29. doi: 10.1146/annurev-med-043024-011141. Online ahead of print.
ABSTRACT
Glucagon-like peptide 1 receptor (GLP-1R) agonists were originally developed as treatments for diabetes and subsequently evolved into weight management medications. These drugs have recently been shown to demonstrate remarkable efficacy in cardiovascular disease, kidney disease, and heart failure with preserved ejection fraction (HFpEF). In this review, we focus on the cardiovascular protective effects of GLP-1R agonists identified from basic studies and outcome trials, including a brief description of those forthcoming soon.
PMID:41160742 | DOI:10.1146/annurev-med-043024-011141